Kelun-Biotech to Present Clinical Updates for Key ADC Programs at 2025 ESMO

We are excited to announce that Kelun-Biotech will present multiple clinical study results at the 2025 ESMO in Berlin, Germany held from October 17–21.

Three Key Presentations to be highlighted at the conference including:

Presidential Symposium: sac-TMT vs. platinum-based chemotherapy in EGFR-mutated NSCLC post-EGFR-TKI progression (OptiTROP-Lung04, Presentation #LBA5).

Oral Report: sac-TMT vs. chemotherapy in HR+/HER2- breast cancer (OptiTROP-Breast02, Presentation #LBA23).

Oral Report: Trastuzumab botidotin (A166) vs. T-DM1 in HER2-positive unresectable or metastatic breast cancer (Presentation #LBA24).

Six additional posters will also be presented including:

SKB315, a novel Claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) in patients with advanced solid tumors including gastric/gastroesophageal junction cancer (GC/GEJC) (Presentation #2139P)

Sacituzumab Tirumotecan (sac-TMT) in participants (pts) with previously treated, advanced, KRAS-mutant NSCLC (Presentation #1945P)

Sacituzumab Tirumotecan (sac-TMT) + pembrolizumab (pembro) for treatment-naive advanced PD-L1 positive NSCLC (Presentation #1949P)

Sacituzumab Tirumotecan (sac-TMT) + pembrolizumab (pembro) in metastatic castration-resistant prostate cancer (mCRPC) (Presentation #2421P)

Sacituzumab Tirumotecan (sac-TMT) monotherapy in advanced/metastatic endometrial carcinoma (EC) (Presentation #1111P)

Efficacy and safety of Sacituzumab Tirumotecan (sac-TMT) monotherapy in advanced/metastatic cervical cancer (Presentation #1168P)

These findings underscore our commitment to advancing innovative ADC therapies for patients with solid tumors. We look forward to sharing these results with the global oncology conference community.